

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Q-CORE MEDICAL LTDApplication No./Patent No.: 10/535,103Filed/Issue Date: May 16, 2005Titled: PERISTALTIC PUMP

Q-CORE MEDICAL LTD, a CORPORATION

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest in;
2. ☐ an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is _____ %); or
3. ☐ the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made) the patent application/patent identified above, by virtue of either:
- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy therefore is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: INVENTORSTo: Q-CORE LTD

The document was recorded in the United States Patent and Trademark Office at

Reel 017295, Frame 0390, or for which a copy thereof is attached.2. From: Q-CORE LTDTo: Q-CORE MEDICAL LTD

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____

To: _____

The document was recorded in the United States Patent and Trademark Office at

Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet(s).

- ☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature

Q-Core Medical Ltd.No. 51-423712-2

Printed or Typed Name

Date

5/07/09

Title

VP Marketing

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ASSIGNMENT

Corporate

Q-Core Ltd (In Liquidation), an Israeli corporation, having a principal place of business at P.O. Box 3341, Petach Tikva 49130, Israel (hereafter the "Assignor"), is the owner by Assignment of the patents and patent applications listed in Exhibit A hereinbelow (hereafter called the "Patents").

Q-Core Medical Ltd., an Israeli corporation, having a place of business at 14 Hamefalsim Street, P.O. Box 3341, Petach Tikva 49130, Israel (hereafter the "Assignee"), desires to acquire all of the rights to the Patents and all inventions described and claimed therein or entitled to the benefit thereof.

THEREFORE, in according to District Court in Tel Aviv tort, dated 4th of February 2009, the Assignor sold to the Assignee, all of it's activity, including the entire right, title and interest in and to the Patents identified below, and all inventions described and claimed therein or entitled to the benefit thereof, in any and all Letters Patent therefor, and in any and all reissues, extensions, renewals, reexaminations, divisions and continuations of such applications or Letters Patent to the full end of the term or terms for which such Letters Patent issue, such entire right, title and interest to be held and enjoyed by the above-named Assignee the same as they would have been held and enjoyed by the Assignor had this Assignment and sale not been made.

The Assignor hereby covenants that it had the full right to convey the entire interest herein assigned, and that it has not executed, and will not execute, any agreement in conflict therewith.

The undersigned is empowered by the District Court in Tel Aviv, to sign this certificate on behalf of the Assignor.

IN WITNESS WHEREOF, executed by the Assignor's undersigned representative on the date following the undersigned's name.

Q-Core Ltd (In Liquidation).

By: Erez Haver, Adv

Title: Special Manager for Q- Core Ltd (In Liquidation)

Date: 11.06.09
אריז חבר, עו"ד - מפרק זמני
לחברת קיו קור בע"מ (נכסיוק זמני)
ח.פ. 51-2341629

EXHIBIT A

Application /patent number	Filing date	Issue date
US Patent Application 10/535,103	2005-05-16	
US Patent Application 11/791,599	2007-05-24	
US Patent 5,996,964		1999-07-12
US Patent 6,095,189		2000-01-08
US Design Application 29/280,013	2007-05-14	
US Design Application 29/280,012	2007-05-14	
US Design Patent D585546		2009-01-29
US Design Patent D585986		2009-02-03
US Design Patent D587365		2009-02-24
US Design Patent D587802		2009-03-03
US Design Patent D574953		2008-08-12

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.